| Kristin A Waters, AAC | |
|
743 Spring St Ne, Gainesville, GA 30501-3715 | |
| (770) 532-7179 | |
| (770) 534-1312 |
| Full Name | Kristin A Waters |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology Assistant |
| Experience | 15 Years |
| Location | 743 Spring St Ne, Gainesville, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265767370 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367H00000X | Anesthesiologist Assistant | 005622 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northeast Georgia Medical Center, Inc | Gainesville, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Anesthesia Associates Of Gainesville, Llc | 2769381771 | 134 |
News Archive
Shield Therapeutics, the independent specialty mineral medicines pharmaceutical company, today announces that it has completed recruitment of patients into its pivotal Phase 3 programme of ST10 for the treatment of iron-deficient anaemia. ST10 is a novel form of ferric iron taken orally.
An international team led by researchers from the Universities of Leicester and Cambridge has announced a breakthrough in identifying people at risk of developing potentially fatal blood clots that can lead to heart attack.
Administering a new form of immunotherapy to children with neuroblastoma, a nervous system cancer, increased the percentage of those who were alive and free of disease progression after two years, according to researchers at the University of California, San Diego School of Medicine and fellow institutions. The percentage rose from 46 percent for children receiving a standard therapy to 66 percent for children receiving immunotherapy plus standard therapy, according to the study published in the Sept. 30, 2010 issue of the New England Journal of Medicine.
A team led by Wayne State University School of Medicine researcher Mark Greenwald, Ph.D., will use a four-year, $2,279,723 competitively renewed grant from the National Institute on Drug Abuse of the National Institutes of Health to explore whether the opioid addiction treatment medication buprenorphine can decrease the magnitude and/or duration of responses to stressors faced by recovering addicts.
› Verified 3 days ago
| Entity Name | Anesthesia Associates Of Gainesville, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457456485 PECOS PAC ID: 2769381771 Enrollment ID: O20040108000009 |
News Archive
Shield Therapeutics, the independent specialty mineral medicines pharmaceutical company, today announces that it has completed recruitment of patients into its pivotal Phase 3 programme of ST10 for the treatment of iron-deficient anaemia. ST10 is a novel form of ferric iron taken orally.
An international team led by researchers from the Universities of Leicester and Cambridge has announced a breakthrough in identifying people at risk of developing potentially fatal blood clots that can lead to heart attack.
Administering a new form of immunotherapy to children with neuroblastoma, a nervous system cancer, increased the percentage of those who were alive and free of disease progression after two years, according to researchers at the University of California, San Diego School of Medicine and fellow institutions. The percentage rose from 46 percent for children receiving a standard therapy to 66 percent for children receiving immunotherapy plus standard therapy, according to the study published in the Sept. 30, 2010 issue of the New England Journal of Medicine.
A team led by Wayne State University School of Medicine researcher Mark Greenwald, Ph.D., will use a four-year, $2,279,723 competitively renewed grant from the National Institute on Drug Abuse of the National Institutes of Health to explore whether the opioid addiction treatment medication buprenorphine can decrease the magnitude and/or duration of responses to stressors faced by recovering addicts.
› Verified 3 days ago
| Entity Name | Capitol Anesthesiology, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245287192 PECOS PAC ID: 5799774642 Enrollment ID: O20040507000216 |
News Archive
Shield Therapeutics, the independent specialty mineral medicines pharmaceutical company, today announces that it has completed recruitment of patients into its pivotal Phase 3 programme of ST10 for the treatment of iron-deficient anaemia. ST10 is a novel form of ferric iron taken orally.
An international team led by researchers from the Universities of Leicester and Cambridge has announced a breakthrough in identifying people at risk of developing potentially fatal blood clots that can lead to heart attack.
Administering a new form of immunotherapy to children with neuroblastoma, a nervous system cancer, increased the percentage of those who were alive and free of disease progression after two years, according to researchers at the University of California, San Diego School of Medicine and fellow institutions. The percentage rose from 46 percent for children receiving a standard therapy to 66 percent for children receiving immunotherapy plus standard therapy, according to the study published in the Sept. 30, 2010 issue of the New England Journal of Medicine.
A team led by Wayne State University School of Medicine researcher Mark Greenwald, Ph.D., will use a four-year, $2,279,723 competitively renewed grant from the National Institute on Drug Abuse of the National Institutes of Health to explore whether the opioid addiction treatment medication buprenorphine can decrease the magnitude and/or duration of responses to stressors faced by recovering addicts.
› Verified 3 days ago
| Entity Name | Ambulatory Anesthesia Of North Georgia, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497870562 PECOS PAC ID: 9931121332 Enrollment ID: O20051229000181 |
News Archive
Shield Therapeutics, the independent specialty mineral medicines pharmaceutical company, today announces that it has completed recruitment of patients into its pivotal Phase 3 programme of ST10 for the treatment of iron-deficient anaemia. ST10 is a novel form of ferric iron taken orally.
An international team led by researchers from the Universities of Leicester and Cambridge has announced a breakthrough in identifying people at risk of developing potentially fatal blood clots that can lead to heart attack.
Administering a new form of immunotherapy to children with neuroblastoma, a nervous system cancer, increased the percentage of those who were alive and free of disease progression after two years, according to researchers at the University of California, San Diego School of Medicine and fellow institutions. The percentage rose from 46 percent for children receiving a standard therapy to 66 percent for children receiving immunotherapy plus standard therapy, according to the study published in the Sept. 30, 2010 issue of the New England Journal of Medicine.
A team led by Wayne State University School of Medicine researcher Mark Greenwald, Ph.D., will use a four-year, $2,279,723 competitively renewed grant from the National Institute on Drug Abuse of the National Institutes of Health to explore whether the opioid addiction treatment medication buprenorphine can decrease the magnitude and/or duration of responses to stressors faced by recovering addicts.
› Verified 3 days ago
| Entity Name | Mak Anesthesia Holdings, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912452939 PECOS PAC ID: 4284917204 Enrollment ID: O20170216001563 |
News Archive
Shield Therapeutics, the independent specialty mineral medicines pharmaceutical company, today announces that it has completed recruitment of patients into its pivotal Phase 3 programme of ST10 for the treatment of iron-deficient anaemia. ST10 is a novel form of ferric iron taken orally.
An international team led by researchers from the Universities of Leicester and Cambridge has announced a breakthrough in identifying people at risk of developing potentially fatal blood clots that can lead to heart attack.
Administering a new form of immunotherapy to children with neuroblastoma, a nervous system cancer, increased the percentage of those who were alive and free of disease progression after two years, according to researchers at the University of California, San Diego School of Medicine and fellow institutions. The percentage rose from 46 percent for children receiving a standard therapy to 66 percent for children receiving immunotherapy plus standard therapy, according to the study published in the Sept. 30, 2010 issue of the New England Journal of Medicine.
A team led by Wayne State University School of Medicine researcher Mark Greenwald, Ph.D., will use a four-year, $2,279,723 competitively renewed grant from the National Institute on Drug Abuse of the National Institutes of Health to explore whether the opioid addiction treatment medication buprenorphine can decrease the magnitude and/or duration of responses to stressors faced by recovering addicts.
› Verified 3 days ago
| Entity Name | Mak Anesthesia Northside Affiliates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609390103 PECOS PAC ID: 7315203718 Enrollment ID: O20171116002499 |
News Archive
Shield Therapeutics, the independent specialty mineral medicines pharmaceutical company, today announces that it has completed recruitment of patients into its pivotal Phase 3 programme of ST10 for the treatment of iron-deficient anaemia. ST10 is a novel form of ferric iron taken orally.
An international team led by researchers from the Universities of Leicester and Cambridge has announced a breakthrough in identifying people at risk of developing potentially fatal blood clots that can lead to heart attack.
Administering a new form of immunotherapy to children with neuroblastoma, a nervous system cancer, increased the percentage of those who were alive and free of disease progression after two years, according to researchers at the University of California, San Diego School of Medicine and fellow institutions. The percentage rose from 46 percent for children receiving a standard therapy to 66 percent for children receiving immunotherapy plus standard therapy, according to the study published in the Sept. 30, 2010 issue of the New England Journal of Medicine.
A team led by Wayne State University School of Medicine researcher Mark Greenwald, Ph.D., will use a four-year, $2,279,723 competitively renewed grant from the National Institute on Drug Abuse of the National Institutes of Health to explore whether the opioid addiction treatment medication buprenorphine can decrease the magnitude and/or duration of responses to stressors faced by recovering addicts.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kristin A Waters, AAC Po Box 1076, Gainesville, GA 30503-1076 Ph: (770) 532-7179 | Kristin A Waters, AAC 743 Spring St Ne, Gainesville, GA 30501-3715 Ph: (770) 532-7179 |
News Archive
Shield Therapeutics, the independent specialty mineral medicines pharmaceutical company, today announces that it has completed recruitment of patients into its pivotal Phase 3 programme of ST10 for the treatment of iron-deficient anaemia. ST10 is a novel form of ferric iron taken orally.
An international team led by researchers from the Universities of Leicester and Cambridge has announced a breakthrough in identifying people at risk of developing potentially fatal blood clots that can lead to heart attack.
Administering a new form of immunotherapy to children with neuroblastoma, a nervous system cancer, increased the percentage of those who were alive and free of disease progression after two years, according to researchers at the University of California, San Diego School of Medicine and fellow institutions. The percentage rose from 46 percent for children receiving a standard therapy to 66 percent for children receiving immunotherapy plus standard therapy, according to the study published in the Sept. 30, 2010 issue of the New England Journal of Medicine.
A team led by Wayne State University School of Medicine researcher Mark Greenwald, Ph.D., will use a four-year, $2,279,723 competitively renewed grant from the National Institute on Drug Abuse of the National Institutes of Health to explore whether the opioid addiction treatment medication buprenorphine can decrease the magnitude and/or duration of responses to stressors faced by recovering addicts.
› Verified 3 days ago
Amelia Jo Wiggins, CAA Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 743 Spring St Ne, Gainesville, GA 30501 Phone: 770-532-7179 | |
Haley Gibson, CAA Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 743 Spring St Ne, Gainesville, GA 30501 Phone: 770-532-7179 | |
Andrew Bryant, AA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 743 Spring St Ne, Gainesville, GA 30501 Phone: 770-532-7179 | |
Kaitlin Schieman, AAC Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 743 Spring St Ne, Gainesville, GA 30501 Phone: 770-532-7179 Fax: 770-532-7179 | |
John Tavis Mclean, AAC Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 743 Spring St Ne, Gainesville, GA 30501 Phone: 770-532-7179 Fax: 770-534-1312 | |
Jeffrey Walker, AA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 743 Spring St Ne, Gainesville, GA 30501 Phone: 770-532-7179 Fax: 770-534-1312 | |
Jesson Bateman, AAC Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 743 Spring St Ne, Gainesville, GA 30501 Phone: 770-532-7179 Fax: 770-534-1312 |